A Study of the Safety and Efficacy of 4 Doses of BI 1744 CL Delivered Via the Respimat in Patients With Asthma.

Condition:   Asthma
Interventions:   Drug: Olodaterol (BI 1744);   Drug: Olodaterol (BI 1744);   Drug: Olodaterol (BI 1744) low;   Drug: Olodaterol (BI 1744) high;   Drug: Formoterol 12 mcg;   Drug: Placebo
Sponsor:   Boehringer Ingelheim Pharmaceuticals
Recruiting – verified September 2010

View full post on ClinicalTrials.gov: “Asthma” | updated in the last 30 days

Safety Study of the Effects of Inhaled Fluticasone Furoate/GW642444 on the Hypothalamic-Pituitary-Adrenal (HPA) Axis

Condition:   Asthma
Interventions:   Drug: Placebo Inhalation Powder;   Drug: Fluticasone Furoate/GW642444 Inhalation Powder;   Drug: Fluticasone Furoate/GW642444 Inhalation Powder;   Drug: Placebo Oral Capsule;   Drug: Prednisolone Oral Capsule
Sponsor:   GlaxoSmithKline
Active, not recruiting – verified October 2010

View full post on ClinicalTrials.gov: “Asthma” | updated in the last 30 days

A Randomised, Double- Blind, Placebo Controlled, Cross-over Efficacy and Safety Comparison of Tiotropium 5 µg Once Daily and Tiotropium 2.5 µg Twice Daily for Four Weeks in Patients With Moderate Persistent Asthma

Condition:   Asthma
Interventions:   Drug: Placebo;   Drug: Tiotropium 5 µg q.d.;   Drug: Tiotropium 2.5 µg b.i.d.
Sponsors:   Boehringer Ingelheim Pharmaceuticals;   Pfizer
Recruiting – verified September 2010

View full post on ClinicalTrials.gov: “Asthma” | updated in the last 30 days

Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticosteroid Treatment for Asthma

Condition:   Asthma
Interventions:   Drug: FP 100mcg BID plus GSK2190915 100mg QD (AM);   Drug: FP 100mcg BID plus GSK2190915 300mg QD (AM);   Drug: FP 100mcg BID plus montelukast 10mg QD (PM);   Drug: FP 100mcg BID plus placebo BID;   Drug: FP/SAL 100/50mcg BID plus placebo BID
Sponsor:   GlaxoSmithKline
Recruiting – verified September 2010

View full post on ClinicalTrials.gov: “Asthma” | updated in the last 30 days